August 21, 2009

An Undervalued Hidden Gem

The Fool writes that one of their Hidden Gems selections, Innophos Holdings appears to be cheap with its 2.1 P/E ratio and 2.4 P/FCF ratio.

August 17, 2009

The Case for Stryker

The Fool makes a good case for owning Stryker in this article. The company is an official Inside Value selection and the Fool owns shares of the company.

August 11, 2009

$30 Price Target on Human Genome Sciences

Notables Calls notes that Leerink has set a new price target of $30 on Human Genome Sciences due to the likely hood of positive Phase II trial data for BLISS-76.

August 5, 2009

On Capital Source

As disclosed here, the Fool owns shares of Capital Source.